Results 251 to 260 of about 2,472,934 (277)
Some of the next articles are maybe not open access.
A Risk-Benefit Assessment of HIV Protease Inhibitors
Drug Safety, 1999The use of triple regimens, often called highly active antiretroviral therapy (HAART), generally involving 2 nucleoside analogues and an HIV protease inhibitor, have been endorsed as the standard of care for persons with HIV initiating therapy by a number of sets of international guidelines.
G J, Moyle, B G, Gazzard
openaire +2 more sources
Intra-Articular Steroid Injection A Risk-Benefit Assessment
Drug Safety, 1990Intra-articular injections with steroids may offer additional help in the treatment of inflammatory joint diseases. The major side effects are the systemic effects of steroids, infectious arthritis and cartilage damage. These are infrequent, however, and to a great extent preventable.
B, Grillet, J, Dequeker
openaire +2 more sources
Risk-benefit Assessment in Animals
1982How do animals themselves assess risks and benefits attached to the alternatives open to them? The foraging context has been chosen for detailed consideration on account of higher fitness presumed to accrue to efficient foragers, and discussion is limited to birds on account of the limited experience of the author.
openaire +1 more source
Silver Products for Medical Indications: Risk-Benefit Assessment
Journal of Toxicology: Clinical Toxicology, 1996Legitimate medicinal use of silver-containing products has dramatically diminished over the last several decades. Recently, however, some manufacturers have begun to enthusiastically promote oral colloidal silver proteins as mineral supplements and for prevention and treatment of many diseases. Indiscriminate use of silver products can lead to toxicity
M C, Fung, D L, Bowen
openaire +2 more sources
Risk-Benefit Assessment in Pediatric Research
2008Abstract Major turning points in history are often recognized only in hindsight. One example of a significant historical change that went almost unnoticed at the time is the statement made by James A. Shannon, director of the National Institutes of Health (NIH), before the National Advisory Health Council (NAHC) on September 28, 1965.
Sumeeta Varma, David Wendler
openaire +1 more source
A Risk-Benefit Assessment of Tacrolimus in Transplantation
Drug Safety, 1995Tacrolimus is a new macrolide immunosuppressant that was isolated from Streptomyces tsukubaensis in 1984. In vitro, on a molecular basis, tacrolimus is 50 to 100 times more potent that cyclosporin. Since 1989, numerous clinical trials have been completed comparing the usefulness of tacrolimus with that of cyclosporin for baseline immunosuppression in ...
M, Winkler, U, Christians
openaire +2 more sources
A Risk-Benefit Assessment of Risperidone in Schizophrenia
Drug Safety, 1995The atypical antipsychotic risperidone combines dopaminergic and serotonergic antagonism. This results in a drug that is both clinically effective, reducing positive and negative symptoms of schizophrenia, and has a low incidence of adverse effects. At a dosage of 4 to 8 mg/day, risperidone is comparable to 10 mg/day of haloperidol.
V A, Curtis, R W, Kerwin
openaire +2 more sources
A Risk-Benefit Assessment of Anti-Obesity Drugs
Drug Safety, 1999This review evaluates the benefits and potential health risks of the currently used drugs that are approved for the pharmacological treatment of obesity. Analysis of several long term clinical trials indicates that all of these drugs are efficient in reducing excess bodyweight, and that the majority of them allow the maintenance of the reduced ...
openaire +2 more sources
MAINTENANCE MEDICATION FOR CHRONIC SCHIZOPHRENICS: RISK/BENEFIT ASSESSMENT
Perspectives in Psychiatric Care, 2009The following are key factors to consider in assessing a patient for long-term neuroleptics: 1. Who--accurate diagnosis of schizophrenia is of primary concern. There are no good prognostic indicators other than a history of repeated relapses and positive responses to neuroleptics. 2.
openaire +2 more sources